Amendment Under 37 C.F.R. § 1.111 U.S. Serial No. 09/214,155

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:


Claim 1. (canceled)

Claim 2. (canceled)

Claim 3. (Amended): A 1,25-dihydroxy-2-methylvitamin D₃ compound, wherein the compound is

- (i) $(20S)-1\alpha$, 25-dihydroxy-2 β -methyl-3 β -vitamin D₃;
- (ii) (20S)-1 β , 25-dihydroxy-2 β -methyl-3 α -vitamin D₃;
- (iii) (20S)- 1α , 25-dihydroxy- 2α -methyl- 3β -vitamin D_3 ; or
- (iv) $(20S)-1\alpha$, 25-dihydroxy- 2α -methyl- 3α -vitamin D_3 .

Claim 4. (Amended): A method for producing a vitamin D₃ compound described in claim 3, comprising reacting an exo-methylene compound of formula (II):



wherein X is a bromine atom or an iodine atom, with an energy compound of formula (III):

Amendment Under 37 C.F.R. § 1.111 U.S. Serial No. 09/214,155

wherein R3 and R4 are each independently a hydrogen atom or a tri (C_1 to C_7 hydrocarbon) silyl) group in the presence of a palladium catalyst, and optionally removing the protecting group of the tri (C_1 to C_7 hydrocarbon) silyl) group, and further wherein the vitamin D_3 compound derivative is

- (i) (20S)- 1α , 25-dihydroxy- 2β -methyl- 3β -vitamin D_3 ;
- (ii) (20S)-1 β , 25-dihydroxy-2 β -methyl-3 α -vitamin D₃;
- (iii) (20S)- 1α , 25-dihydroxy- 2α -methyl- 3β -vitamin D_3 ; or
- (iv) (20S)- 1α , 25-dihydroxy- 2α -methyl- 3α -vitamin D_3 .